A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia

Sophie Edtmayer, Agnieszka Witalisz-Siepracka, Bernhard Zdársky, Kerstin Heindl, Stefanie Weiss, Thomas Eder, Sayantanee Dutta, Uwe Graichen, Sascha Klee, Omar Sharif, Rotraud Wieser, Balázs Győrffy, Valeria Poli, Emilio Casanova, Heinz Sill, Florian Grebien, Dagmar Stoiber*

*Korrespondierende:r Autor:in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed)Artikel in Fachzeitschrift

Abstract

Signal transducer and activator of transcription 3 (STAT3) is frequently overexpressed in patients with acute myeloid leukemia (AML). STAT3 exists in two distinct alternatively spliced isoforms, the full-length isoform STAT3α and the C-terminally truncated isoform STAT3β. While STAT3α is predominantly described as an oncogenic driver, STAT3β has been suggested to act as a tumor suppressor. To elucidate the role of STAT3β in AML, we established a mouse model of STAT3β-deficient, MLL-AF9-driven AML. STAT3β deficiency significantly shortened survival of leukemic mice confirming its role as a tumor suppressor. Furthermore, RNA sequencing revealed enhanced STAT1 expression and interferon (IFN) signaling upon loss of STAT3β. Accordingly, STAT3β-deficient leukemia cells displayed enhanced sensitivity to blockade of IFN signaling through both an IFNAR1 blocking antibody and the JAK1/2 inhibitor Ruxolitinib. Analysis of human AML patient samples confirmed that elevated expression of IFN-inducible genes correlated with poor overall survival and low STAT3β expression. Together, our data corroborate the tumor suppressive role of STAT3β in a mouse model in vivo. Moreover, they provide evidence that its tumor suppressive function is linked to repression of the STAT1-mediated IFN response. These findings suggest that the STAT3β/α mRNA ratio is a significant prognostic marker in AML and holds crucial information for targeted treatment approaches. Patients displaying a low STAT3β/α mRNA ratio and unfavorable prognosis could benefit from therapeutic interventions directed at STAT1/IFN signaling.

OriginalspracheEnglisch
Aufsatznummer369
Seiten (von - bis)369
FachzeitschriftCell Death and Disease
Jahrgang15
Ausgabenummer5
DOIs
PublikationsstatusVeröffentlicht - 28 Mai 2024

Fingerprint

Untersuchen Sie die Forschungsthemen von „A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren